International Business Machines Corp. (NYSE:IBM) Watson Health released it has completed $2.6B takeover of Truven Health Analytics, analytics and insights. Truven brings in excess of 8,500 clients to Watson Health portfolio, comprising U.S. federal and state government agencies, employers, health plans, hospitals, clinicians and life sciences companies. Data and insights from Truven inform benefit decisions for one in three Americans.
With the completion of the acquisition, IBM and Truven data scientists will start the process of using Watson Health’s cognitive capabilities to derive insights from Truven’s health data. Through Truven, IBM gains extensive data spanning cost, claims, quality and outcomes information.
IBM anticipates that healthcare organizations will tap into this cloud-based data to take before disparate data sets, comprising vast amounts of structured and unstructured data, and combine them together to create exclusive insights that help inform a broad range of health decisions in an effort to improve the quality of care at lower cost. Data from Truven, together with an array of solutions and services, will also help optimize IBM offerings for value-based care.
This is IBM’s fourth major health data related acquisition since launching the Watson Health unit in April 2015. Truven will become part of IBM Watson Health and the acquisition bolsters the business unit’s global talent footprint to over 5,000 employees, comprising hundreds of clinicians, epidemiologists, statisticians, healthcare administrators, policy experts and healthcare consultants.
IBM Teams Up With Pfizer
International Business Machines Corp. (NYSE:IBM) and Pfizer Inc. (NYSE:PFE) released that a partnership to develop monitoring solutions planed at transforming how health care providers deliver care to patients suffering from Parkinson’s disease, according to Benzinga.
The President of Pfizer Worldwide Research and Development, Mikael Dolsten stated that they have an opportunity to potentially redefine how they think about patient outcomes and 24/7 monitoring, by combining Pfizer’s scientific, medical and regulatory expertise with IBM’s ability to integrate and interpret complex data in innovative ways.
He added, “The key to their success will be to deliver a reliable, scalable system of measurement and analysis that would help inform our clinical programs across important areas of unmet medical need, potentially accelerating the drug development and regulatory approval processes and helping us to get better therapies to patients, faster.”